2035 – CentAK® IAA M

The CentAK® IAA M is a quantitative immunoassay for the determination of antibodies against insulin (IAA) in human serum. The CentAK® IAA M is intended as an aid in the diagnosis of autoimmune diabetes mellitus type 1 in conjunction with other clinical and laboratory findings.

Genetic susceptibility and exposure to environmental factors are probable causes of type 1 diabetes, alternatively referred to as insulin-dependent diabetes mellitus (IDDM), a chronic autoimmune destruction of the insulin-secreting pancreatic beta cells. This condition is believed to be completely asymptomatic until about 80-90% of the cells are destroyed, a process that may take years to complete, occurring regardless of age. Circulating autoantibodies to beta cell antigens are characteristic of the preclinical phase of the autoimmune process.

Preclinical phase of the autoimmune process is evident by the presence of autoantibodies to beta cell antigens, especially insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD) and tyrosine phosphatase ICA 512 (IA2), several years prior to appearance of clinical symptoms. Detection of IAA in individuals prior to any intake/treatment with insulin, as opposed to insulin antibodies (IAb), is a proof of ongoing deterioration of the pancreatic beta cells in type 1 diabetes. Furthermore, IAA proves to be important in the early detection of type 1 diabetes due to their significantly elevated levels during the disease developmental stage in childhood and also being the first autoantibodies to be detected before onset of the disease, in other words, an inverse correlation between the prevalence of IAA and the diagnostic stage.

The current method for investigating early detection of type 1 diabetes involves a combination of the IAA measurement, with that of antibodies to glutamic acid decarboxylase (GAD65 Ab) and protein tyrosine phosphatase-like antigen IA2.

Radioimmunoassays are widely used for the determination of specific antibodies. For this purpose tracer molecules composed of antigens conjugated to radioactive components detect specific antibodies in the patient´s sample. Protein A binds antibodies from the sample and allows for the simple separation of agglutinated immune complexes from the reaction mixture by centrifugation. The radioactivity of the precipitate is measured and proportional to the antibody activity in the sample.

The immunoassay is designed for manual professional in vitro diagnostic use.

Product summary

Title CentAK® IAA M
Product code 2035
Indication Type 1 Diabetes
Description Radioimmunoassay for the quantitative determination of antibodies against insulin (IAA) in human serum
Format Radioimmunoassay
Total incubation time Overnight
Sample volume 20 µL
No. of determinations 100 (93 x 1) + 5 x Calibrators and 2 x Controls


Restricted downloads - Password required